1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Lundbeck Breaks Into MAb Development, Adds To Suite Of Parkinson's Candidates

 
• By John Davis

Denmark's mid-sized biopharma, Lundbeck, has taken another potential Parkinson's disease therapeutic into early clinical studies, the third this year, and this time it's a monoclonal antibody, not a small molecule.  

Brain decline and dementia or aging as memory loss concept for brain cancer decay or an Alzheimer's disease with old rusting mechanical gears and cog wheels in the shape of a human head with rust.
• Source: Shutterstock

Denmark's mid-sized pharmaceutical company, Lundbeck Inc., has moved its first-ever monoclonal antibody into clinical studies by taking the anti-alpha-synuclein antibody, Lu AF82422, into the clinic, joining a handful of MAb-based therapies that are being evaluated by biopharma companies in early-stage clinical studies for Parkinson's disease.

Lundbeck is well known as a specialty developer of drugs for psychiatric and neurological disorders, and the aging antidepressant, Cipralex/Lexapro (escitalopram), was still the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

 
• By Sushmita Panda

The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.